Irinotecan (Camptosar) in Patients With Advanced Sarcomas

Summary

Primary Objectives: 1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan, delivered via a low-dose protracted schedule to patients with advanced sarcoma. 2. To determine the toxicity profile of irinotecan, using a protracted schedule, in this pretreated patient population.

Timeline

Start

2003-03

Primary completion

2007-08

Completion

2012-01

Drugs

Indications